SOFT and TEXT treatment hazard ratios and Kaplan-Meier estimates

Treatment effect hazard ratios (95% CIs) and Kaplan-Meier estimates of eight-year times to event for four endpoints in the HR-positive/HER2-negative subgroups of SOFT and TEXT, for the two primary analysis populations (ie, SOFT overall and combined TEXT plus SOFT) and by cohort (defined by trial and chemotherapy use).^[1] The median follow-up was eight and nine years in SOFT and TEXT, respectively.

CI: confidence interval; E+OFS: exemestane plus ovarian function suppression; HER2: human epidermal growth factor receptor 2; HR: hormone receptor; SOFT: Suppression of Ovarian Function Trial; T: tamoxifen; T+OFS: tamoxifen plus ovarian function suppression; TEXT: Tamoxifen and Exemestane Trial.

Reference:

Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018; 379:122.

Reproduced with permission from: Regan MM, Fleming GF, Walley B, et al. Adjuvant systemic treatment of premenopausal women with hormone receptor–positive early breast cancer: Lights and shadows. J Clin Oncol 2019; 37(11):862-866. Copyright © 2019 American Society of Clinical Oncology. https://ascopubs.org/journal/jco.

Graphic 121304 Version 3.0

خرید پکیج

SOFT and TEXT treatment hazard ratios and Kaplan-Meier estimates